FIT for CRC Screening

In Europe, colorectal cancer (CRC) is the most prevalent of all tumours, with 471,000 new cases diagnosed per year and second only to lung cancer in terms of deaths. Yet studies show that it is possible to significantly reduce mortality when one adopts population-based CRC screening programmes.

In 2010, a European Parliament resolution called for the adoption of primary prevention and early diagnosis through screening. Some European member states have already started population-based screening programmes, either on a national or regional scale. Others are still assessing and defining strategies for implementation of CRC screening programs or already in the pilot phase. Population between the ages of 50 and 74 are often eligible and invited to participate in CRC screening programs to detect bowel cancer early on.

Due to its simplicity and proven superior performance, the quantitative faecal immunochemical test, or FIT, is currently considered the best, non-invasive Faecal Occult Blood (FOB) test for Screening.


“The FIT Test has a major advantage as it is quantitative so that no interpretation from the doctor is required. Another benefit is you can perform it in high volume because the throughput is fast: you can easily analyse a few thousand tests per day.” 

W.W.J. Spijker, CEO Screening Organisation in The Netherlands

“With simple lab testing you can help save lives.”

Lizet Bosman-Weijzen, Analyst, Geleen, The Netherlands

It's so easy

The test is hygienic, simple and you can't do anything wrong – convince yourself!